MentionFox
Home › 5%+ stakes › Manufacturing (industry group 28), latest filing in October 2026
5%+ stakes

Manufacturing (industry group 28), latest filing in October 2026

28 companies with 5%+ holders, every filing linked: Annovis Bio, Inc., Atea Pharmaceuticals, Inc., aTYR PHARMA INC, China SXT Pharmaceuticals, Inc., Clorox, Corcept Therapeutics Incorporated and more. Each section is the company's full record from its filings, newest filings first within each section.

28 companies with 5%+ holders on this page (Manufacturing (industry group 28), latest filing in October 2026), each linked to its filing, starting with Annovis Bio, Inc., Atea Pharmaceuticals, Inc., aTYR PHARMA INC. Free check on any of them: https://mentionfox.com/check

On this page

Annovis Bio, Inc.

At 5% or more1
Filings3
Latest filing2026-10-15

Annovis Bio, Inc. has 3 Schedule 13D or 13G filings on record since 2026-07-29. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Highbridge Capital Management, LLC6.1%2,775,578SCHEDULE 13G, 2026-08-142026-06-30
Empery Asset Management, LP4.99%2,241,537SCHEDULE 13G/A, 2026-10-152026-09-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Highbridge Capital Management, LLC2,775,57802,775,5780SCHEDULE 13G, 2026-08-14
Empery Asset Management, LP02,241,53702,241,537SCHEDULE 13G/A, 2026-10-15
Ryan M. Lane02,241,53702,241,537SCHEDULE 13G/A, 2026-10-15

The latest filing identifies Annovis Bio, Inc. by CUSIP 03615A108 and gives its principal executive office as 101 Lindenwood Drive, Suite 225, Malvern, PA 19355 (SCHEDULE 13G/A, 2026-10-15).

FiledHolderPercentFiling
2026-07-29Empery Asset Management, LP5.64%SCHEDULE 13G
2026-08-14Highbridge Capital Management, LLC6.1%SCHEDULE 13G
2026-10-15Empery Asset Management, LP4.99%SCHEDULE 13G/A

Atea Pharmaceuticals, Inc.

At 5% or more3
Filings6
Latest filing2026-10-06

Atea Pharmaceuticals, Inc. has 6 Schedule 13D or 13G filings on record since 2025-08-06. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Fmr LLC15%11,950,772SCHEDULE 13G/A, 2026-05-062026-03-31
Leonard Braden Michael9.9%7,810,000SCHEDULE 13G, 2026-02-092025-12-31
Tang Capital Management, LLC6%4,814,700SCHEDULE 13G, 2026-10-062026-10-06
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Fmr LLC11,949,098011,950,7720SCHEDULE 13G/A, 2026-05-06
Abigail P. Johnson0011,950,7720SCHEDULE 13G/A, 2026-05-06
BML Investment Partners, L.P.07,490,00007,490,000SCHEDULE 13G, 2026-02-09
Leonard Braden Michael320,0007,490,000320,0007,490,000SCHEDULE 13G, 2026-02-09
Tang Capital Management, LLC04,814,70004,814,700SCHEDULE 13G, 2026-10-06
Kevin Tang04,814,70004,814,700SCHEDULE 13G, 2026-10-06
Tang Capital Partners, LP02,488,51902,488,519SCHEDULE 13G, 2026-10-06
Tang Capital Partners International, LP01,665,07701,665,077SCHEDULE 13G, 2026-10-06
Tang Capital Partners Iii, Inc0661,1040661,104SCHEDULE 13G, 2026-10-06
Tang Capital Partners Iv, Inc0000SCHEDULE 13G, 2026-10-06
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Atea Pharmaceuticals, Inc. by CUSIP 04683R106 and gives its principal executive office as 225 Franklin Street, Suite 2100, Boston, MA 02110 (SCHEDULE 13G, 2026-10-06).

FiledHolderPercentFiling
2025-08-06Fmr LLC6.7%SCHEDULE 13G/A
2025-12-05Fmr LLC11.6%SCHEDULE 13G/A
2026-02-09Leonard Braden Michael9.9%SCHEDULE 13G
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-05-06Fmr LLC15%SCHEDULE 13G/A
2026-10-06Tang Capital Management, LLC6%SCHEDULE 13G

aTYR PHARMA INC

At 5% or more0
Filings10
Latest filing2026-11-04

aTYR PHARMA INC has 10 Schedule 13D or 13G filings on record since 2025-07-17. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Fmr LLC2.5%2,471,418SCHEDULE 13G/A, 2026-08-062026-06-30
BlackRock, Inc.1.8%1,725,072SCHEDULE 13G/A, 2026-07-272026-06-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Federated Hermes, Inc.0%0SCHEDULE 13G/A, 2026-11-042026-10-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Fmr LLC2,464,14102,471,4180SCHEDULE 13G/A, 2026-08-06
Abigail P. Johnson002,471,4180SCHEDULE 13G/A, 2026-08-06
BlackRock, Inc.1,725,07201,725,0720SCHEDULE 13G/A, 2026-07-27
Federated Hermes, Inc.0000SCHEDULE 13G/A, 2026-11-04
Voting Shares Irrevocable Trust0000SCHEDULE 13G/A, 2026-11-04
Thomas R. Donahue0000SCHEDULE 13G/A, 2026-11-04
Ann C. Donahue0000SCHEDULE 13G/A, 2026-11-04
J. Christopher Donahue0000SCHEDULE 13G/A, 2026-11-04

The latest filing identifies aTYR PHARMA INC by CUSIP 002120202 and gives its principal executive office as 10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121 (SCHEDULE 13G/A, 2026-11-04).

FiledHolderPercentFiling
2025-07-17BlackRock, Inc.6.5%SCHEDULE 13G
2025-07-29The Vanguard Group5.23%SCHEDULE 13G
2025-10-07Federated Hermes, Inc.10.76%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-06-05Fmr LLC6.1%SCHEDULE 13G/A
2026-07-08Federated Hermes, Inc.8.68%SCHEDULE 13G/A
2026-07-27BlackRock, Inc.1.8%SCHEDULE 13G/A
2026-08-06Fmr LLC2.5%SCHEDULE 13G/A
2026-10-07Federated Hermes, Inc.5.06%SCHEDULE 13G/A
2026-11-04Federated Hermes, Inc.0%SCHEDULE 13G/A

China SXT Pharmaceuticals, Inc.

At 5% or more5
Filings5
Latest filing2026-10-15

China SXT Pharmaceuticals, Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-07. 5 holders' latest filing reports 5% or more of class a ordinary shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Orca Capital AG9.9%1,112,788SCHEDULE 13G, 2026-10-152026-10-08
Foong Soon Hong, Randy9.12%10,588,240SCHEDULE 13G, 2025-08-072025-07-29
Tan Soo Seng8.95%10,392,160SCHEDULE 13G, 2025-08-072025-07-29
Tan Cheng Guan8.79%10,196,080SCHEDULE 13G, 2025-08-072025-07-29
Ching Choon Hwa8.45%9,803,920SCHEDULE 13G, 2025-08-072025-07-29
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Orca Capital AG1,112,78801,112,7880SCHEDULE 13G, 2026-10-15
Foong Soon Hong, Randy10,588,240010,588,2400SCHEDULE 13G, 2025-08-07
Tan Cheng Guan10,196,080010,196,0800SCHEDULE 13G, 2025-08-07
Ching Choon Hwa9,803,92009,803,9200SCHEDULE 13G, 2025-08-07

The latest filing identifies China SXT Pharmaceuticals, Inc. by CUSIP G2161P157 and gives its principal executive office as 178 Taidong Rd North, Taizhou, Jiangsu (SCHEDULE 13G, 2026-10-15).

FiledHolderPercentFiling
2025-08-07Foong Soon Hong, Randy9.12%SCHEDULE 13G
2025-08-07Tan Cheng Guan8.79%SCHEDULE 13G
2025-08-07Tan Soo Seng8.95%SCHEDULE 13G
2025-08-07Ching Choon Hwa8.45%SCHEDULE 13G
2026-10-15Orca Capital AG9.9%SCHEDULE 13G

Clorox

At 5% or more2
Filings4
Latest filing2026-10-27

Clorox has 4 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.35%8,889,552SCHEDULE 13G, 2026-04-292026-03-31
BlackRock, Inc.6.3%7,665,771SCHEDULE 13G/A, 2026-10-272026-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management1,039,11508,889,5520SCHEDULE 13G, 2026-04-29
BlackRock, Inc.7,279,13907,665,7710SCHEDULE 13G/A, 2026-10-27
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Clorox by CUSIP 189054109 and gives its principal executive office as 1221 Broadway, OAKLAND, CA 94612-1888 (SCHEDULE 13G/A, 2026-10-27).

FiledHolderPercentFiling
2025-07-17BlackRock, Inc.8.1%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management7.35%SCHEDULE 13G
2026-10-27BlackRock, Inc.6.3%SCHEDULE 13G/A
DateRecordFigureOur pageSource
October 29, 2026Leadership change: Fabian Garcia appointed, Chief Executive Officer, and 2 more—Leadership changesSource
June 17, 2026Leadership change: Chris Hyder appointed, Chief Operating Officer, and 1 more—Leadership changesSource
May 28, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

Corcept Therapeutics Incorporated

At 5% or more2
Filings6
Latest filing2026-10-27

Corcept Therapeutics Incorporated has 6 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.8.9%9,614,217SCHEDULE 13G/A, 2026-10-272026-09-30
Ingalls & Snyder LLC6.8%7,263,466SCHEDULE 13G/A, 2026-04-212025-12-31
Renaissance Technologies LLC4.9%5,261,628SCHEDULE 13G/A, 2026-08-132026-04-01
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.9,288,02509,614,2170SCHEDULE 13G/A, 2026-10-27
Ingalls & Snyder LLC0007,263,466SCHEDULE 13G/A, 2026-04-21
Renaissance Technologies LLC5,261,62805,261,6280SCHEDULE 13G/A, 2026-08-13
Renaissance Technologies Holdings Corporation5,261,62805,261,6280SCHEDULE 13G/A, 2026-08-13
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Corcept Therapeutics Incorporated by CUSIP 218352102 and gives its principal executive office as 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA 94065 (SCHEDULE 13G/A, 2026-10-27).

FiledHolderPercentFiling
2025-07-17BlackRock, Inc.10.9%SCHEDULE 13G/A
2026-02-12Renaissance Technologies LLC5.47%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-21Ingalls & Snyder LLC6.8%SCHEDULE 13G/A
2026-08-13Renaissance Technologies LLC4.9%SCHEDULE 13G/A
2026-10-27BlackRock, Inc.8.9%SCHEDULE 13G/A
DateRecordFigureOur pageSource
September 23, 2026Leadership change: Sean Maduck departs, President—Leadership changesSource

Eli Lilly And Company

At 5% or more2
Filings8
Latest filing2026-10-19

Eli Lilly And Company has 8 Schedule 13D or 13G filings on record since 2025-10-30. 2 holders' latest filing reports 5% or more of common stock, without par value. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Lilly Endowment, Inc.9.6%90,066,978SCHEDULE 13G/A, 2026-10-192026-09-30
Vanguard Capital Management6.48%61,295,605SCHEDULE 13G, 2026-05-012026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Lilly Endowment, Inc.90,066,978090,066,9780SCHEDULE 13G/A, 2026-10-19
Vanguard Capital Management7,933,831061,295,6050SCHEDULE 13G, 2026-05-01

The latest filing identifies Eli Lilly And Company by CUSIP 532457108 and gives its principal executive office as LILLY CORPORATE CTR, DROP CODE 1094, INDIANAPOLIS, IN 46285 (SCHEDULE 13G/A, 2026-10-19).

FiledHolderPercentFiling
2025-10-30The Vanguard Group8.55%SCHEDULE 13G/A
2025-10-30Lilly Endowment, Inc.10.1%SCHEDULE 13G/A
2026-01-23Lilly Endowment, Inc.9.8%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-20Lilly Endowment, Inc.9.7%SCHEDULE 13G/A
2026-05-01Vanguard Capital Management6.48%SCHEDULE 13G
2026-07-23Lilly Endowment, Inc.9.6%SCHEDULE 13G/A
2026-10-19Lilly Endowment, Inc.9.6%SCHEDULE 13G/A

Genmab A/S

At 5% or more2
Filings5
Latest filing2026-10-05

Genmab A/S has 5 Schedule 13D or 13G filings on record since 2025-11-14. 2 holders' latest filing reports 5% or more of ordinary shares, nominal value dkk 1 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Darwin Global Management, Ltd.5.9%3,668,310SCHEDULE 13G, 2026-10-052026-09-28
Orbis Investment Management Ltd5.3%3,320,695SCHEDULE 13G/A, 2026-08-142026-06-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Darwin Global Management, Ltd.03,668,31003,668,310SCHEDULE 13G, 2026-10-05
Dr. Abhishek Trehan03,668,31003,668,310SCHEDULE 13G, 2026-10-05
Darwin Global Master Fund, Ltd.03,569,74603,569,746SCHEDULE 13G, 2026-10-05
Orbis Investment Management Ltd3,320,69503,320,6950SCHEDULE 13G/A, 2026-08-14
Allan Gray Australia Pty Ltd7,81007,8100SCHEDULE 13G/A, 2026-08-14

The latest filing identifies Genmab A/S by CUSIP 372303206 and gives its principal executive office as TOLDBODGADE 33, 1253 COPENHAGEN K (SCHEDULE 13G, 2026-10-05).

FiledHolderPercentFiling
2025-11-14Orbis Investment Management Ltd5.8%SCHEDULE 13G
2026-02-17Orbis Investment Management Ltd6.6%SCHEDULE 13G/A
2026-05-15Orbis Investment Management Ltd5.5%SCHEDULE 13G/A
2026-08-14Orbis Investment Management Ltd5.3%SCHEDULE 13G/A
2026-10-05Darwin Global Management, Ltd.5.9%SCHEDULE 13G

Harmony Biosciences Holdings, Inc.

At 5% or more3
Filings7
Latest filing2026-10-27

Harmony Biosciences Holdings, Inc. has 7 Schedule 13D or 13G filings on record since 2025-11-05. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.12.6%7,361,888SCHEDULE 13G/A, 2026-10-272026-09-30
Fmr LLC5.4%3,112,812SCHEDULE 13G/A, 2026-02-052025-12-31
Vanguard Portfolio Management5.08%2,943,383SCHEDULE 13G, 2026-07-312026-06-30
Antonio J. Gracias3.2%1,831,327SCHEDULE 13G/A, 2025-11-142025-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.7,269,05107,361,8880SCHEDULE 13G/A, 2026-10-27
Vanguard Portfolio Management62,89402,943,3830SCHEDULE 13G, 2026-07-31
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Harmony Biosciences Holdings, Inc. by CUSIP 413197104 and gives its principal executive office as 630 W GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING, PA 19462 (SCHEDULE 13G/A, 2026-10-27).

FiledHolderPercentFiling
2025-11-05Fmr LLC6.7%SCHEDULE 13G/A
2025-11-14Antonio J. Gracias3.2%SCHEDULE 13G/A
2026-02-05Fmr LLC5.4%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-07-28BlackRock, Inc.11.3%SCHEDULE 13G/A
2026-07-31Vanguard Portfolio Management5.08%SCHEDULE 13G
2026-10-27BlackRock, Inc.12.6%SCHEDULE 13G/A
DateRecordFigureOur pageSource
October 30, 2026Leadership change: Peter Anastasiou appointed, President and Chief Executive Officer—Leadership changesSource
October 13, 2026Leadership change: Peter Anastasiou appointed, President and Chief Executive Officer—Leadership changesSource
July 16, 2026Leadership change: Stephen Mollichella appointed, Principal Financial Officer—Leadership changesSource
April 14, 2026Leadership change: Glenn Reicin appointed, Chief Financial Officer—Leadership changesSource
April 2, 2026Leadership change: Antonio Gracias departs, Director—Leadership changesSource

Harrow, Inc.

At 5% or more3
Filings6
Latest filing2026-11-06

Harrow, Inc. has 6 Schedule 13D or 13G filings on record since 2026-03-11. 3 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.7.4%2,757,783SCHEDULE 13G/A, 2026-10-272026-09-30
Opaleye Management Inc.5.62%2,105,000SCHEDULE 13G/A, 2026-11-062026-09-30
Daniel Kaufman5.04%1,878,000SCHEDULE 13G, 2026-03-112026-03-10
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.2,692,84802,757,7830SCHEDULE 13G/A, 2026-10-27
Opaleye Management Inc.02,105,00002,105,000SCHEDULE 13G/A, 2026-11-06
Opaleye, L.P.02,105,00002,105,000SCHEDULE 13G/A, 2026-11-06
James Silverman02,105,00002,105,000SCHEDULE 13G/A, 2026-11-06
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Harrow, Inc. by CUSIP 415858109 and gives its principal executive office as 1A Burton Hills Blvd, Suite 200, Nashville, TN 37215 (SCHEDULE 13G/A, 2026-11-06).

FiledHolderPercentFiling
2026-03-11Daniel Kaufman5.04%SCHEDULE 13G
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-05-11Opaleye Management Inc.7.61%SCHEDULE 13G/A
2026-07-31Opaleye Management Inc.6.44%SCHEDULE 13G/A
2026-10-27BlackRock, Inc.7.4%SCHEDULE 13G/A
2026-11-06Opaleye Management Inc.5.62%SCHEDULE 13G/A
DateRecordFigureOur pageSource
November 17, 2025Acquired Melt Pharmaceuticals, Inc.$4.30MAcquisitionSource

Innospec Inc

At 5% or more3
Filings7
Latest filing2026-10-07

Innospec Inc has 7 Schedule 13D or 13G filings on record since 2026-03-27. 3 holders' latest filing reports 5% or more of common stock sh. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Portfolio Management7.51%1,870,254SCHEDULE 13G, 2026-04-292026-03-31
Dimensional Fund Advisors LP5.3%1,305,038SCHEDULE 13G, 2026-07-142026-06-30
Vanguard Capital Management5.22%1,300,194SCHEDULE 13G, 2026-04-302026-03-31
Allspring Global Investments Holdings, LLC4.7%1,161,421SCHEDULE 13G/A, 2026-10-072026-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Dimensional Fund Advisors LP1,279,71701,305,0380SCHEDULE 13G, 2026-07-14
Allspring Global Investments Holdings, LLC1,160,59701,161,4210SCHEDULE 13G/A, 2026-10-07

The latest filing identifies Innospec Inc by CUSIP 45768S105 and gives its principal executive office as 8310 SOUTH VALLEY HIGHWAY, SUITE 350, ENGLEWOOD, CO 80112 (SCHEDULE 13G/A, 2026-10-07).

FiledHolderPercentFiling
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Portfolio Management7.51%SCHEDULE 13G
2026-04-30Vanguard Capital Management5.22%SCHEDULE 13G
2026-07-14Dimensional Fund Advisors LP5.3%SCHEDULE 13G
2026-07-31Allspring Global Investments Holdings, LLC7.7%SCHEDULE 13G/A
2026-10-07Allspring Global Investments Holdings, LLC4.7%SCHEDULE 13G
2026-10-07Allspring Global Investments Holdings, LLC4.7%SCHEDULE 13G/A
DateRecordFigureOur pageSource
June 4, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

Innoviva Inc

At 5% or more5
Filings11
Latest filing2026-10-27

Innoviva Inc has 11 Schedule 13D or 13G filings on record since 2025-08-05. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.15.4%11,138,961SCHEDULE 13G/A, 2026-10-272026-09-30
Dimensional Fund Advisors LP5.8%4,360,401SCHEDULE 13G/A, 2026-01-212025-12-31
Vanguard Portfolio Management5.79%4,288,063SCHEDULE 13G, 2026-04-292026-03-31
Renaissance Technologies LLC5.63%4,210,172SCHEDULE 13G/A, 2026-02-122025-12-31
Vanguard Capital Management5.01%3,704,185SCHEDULE 13G, 2026-07-312026-06-30
Franklin Resources, Inc.4.5%2,827,918SCHEDULE 13G/A, 2025-08-052025-06-30
Bank Of Nova Scotia3.37%2,179,005SCHEDULE 13G/A, 2025-10-082025-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.10,924,497011,138,9610SCHEDULE 13G/A, 2026-10-27
Vanguard Portfolio Management63,11204,288,0630SCHEDULE 13G, 2026-04-29
Vanguard Capital Management546,13203,704,1850SCHEDULE 13G, 2026-07-31
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Innoviva Inc by CUSIP 45781M101 and gives its principal executive office as 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME, CA 94010 (SCHEDULE 13G/A, 2026-10-27).

FiledHolderPercentFiling
2025-08-05Franklin Resources, Inc.4.5%SCHEDULE 13G/A
2025-08-06Bank Of Nova Scotia11.36%SCHEDULE 13G
2025-08-13Renaissance Technologies LLC7.56%SCHEDULE 13G/A
2025-09-03Bank Of Nova Scotia5.55%SCHEDULE 13G/A
2025-10-08Bank Of Nova Scotia3.37%SCHEDULE 13G/A
2026-01-21Dimensional Fund Advisors LP5.8%SCHEDULE 13G/A
2026-02-12Renaissance Technologies LLC5.63%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Portfolio Management5.79%SCHEDULE 13G
2026-07-31Vanguard Capital Management5.01%SCHEDULE 13G
2026-10-27BlackRock, Inc.15.4%SCHEDULE 13G/A
DateRecordFigureOur pageSource
May 18, 2026Leadership change: Josephine Linden appointed, Director, and 1 more—Leadership changesSource

Journey Medical Corp

At 5% or more1
Filings6
Latest filing2026-10-09

Journey Medical Corp has 6 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock sh. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Wasatch Advisors LP11%2,449,253SCHEDULE 13G/A, 2026-10-092026-09-30
Vanguard Capital Management3.59%774,556SCHEDULE 13G/A, 2026-07-312026-06-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Wasatch Advisors LP2,278,73002,449,2530SCHEDULE 13G/A, 2026-10-09
Vanguard Capital Management99,3710774,5560SCHEDULE 13G/A, 2026-07-31

The latest filing identifies Journey Medical Corp by CUSIP 48115J109 and gives its principal executive office as 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE, AZ 85258 (SCHEDULE 13G/A, 2026-10-09).

FiledHolderPercentFiling
2025-08-14Wasatch Advisors LP6.7%SCHEDULE 13G/A
2026-04-06Wasatch Advisors LP10%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management5.65%SCHEDULE 13G
2026-07-15Wasatch Advisors LP13.3%SCHEDULE 13G/A
2026-07-31Vanguard Capital Management3.59%SCHEDULE 13G/A
2026-10-09Wasatch Advisors LP11%SCHEDULE 13G/A

Jupiter Neurosciences, Inc.

At 5% or more1
Filings4
Latest filing2026-10-26

Jupiter Neurosciences, Inc. has 4 Schedule 13D or 13G filings on record since 2026-08-28. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
PharmAla Biotech Holdings Inc.10.1%132,867SCHEDULE 13G/A, 2026-10-262026-09-30
Orca Capital AG3.3%39,945SCHEDULE 13G/A, 2026-08-282026-08-21
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
PharmAla Biotech Holdings Inc.132,8670132,8670SCHEDULE 13G/A, 2026-10-26
Orca Capital AG39,945039,9450SCHEDULE 13G/A, 2026-08-28

The latest filing identifies Jupiter Neurosciences, Inc. by CUSIP 48208B203 and gives its principal executive office as 1001 North US HIghway 1, Suite 504, Jupiter, FL 33477 (SCHEDULE 13G/A, 2026-10-26).

FiledHolderPercentFiling
2026-08-28Orca Capital AG8.4%SCHEDULE 13G
2026-08-28Orca Capital AG3.3%SCHEDULE 13G/A
2026-09-22PharmAla Biotech Holdings Inc.17.3%SCHEDULE 13G
2026-10-26PharmAla Biotech Holdings Inc.10.1%SCHEDULE 13G/A
DateRecordFigureOur pageSource
September 4, 2026Form D, private offering$775K soldForm D pageSource
June 30, 2026Leadership change: Tomas J. Philipson appointed, Director—Leadership changesSource
June 22, 2026Leadership change: Allison W. Brady departs, Director—Leadership changesSource

Karbon-X Corp

At 5% or more1
Filings3
Latest filing2026-10-19

Karbon-X Corp has 3 Schedule 13D or 13G filings on record since 2025-09-17. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Morsevo Trade, Inc6.7%7,243,923SCHEDULE 13D/A, 2026-10-192026-09-25
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Morsevo Trade, Inc7,243,92307,243,9230SCHEDULE 13D/A, 2026-10-19

The latest filing identifies Karbon-X Corp by CUSIP 19179P109 and gives its principal executive office as 6575 West Loop South, Suite 500, Bellaire, TX 77401 (SCHEDULE 13D/A, 2026-10-19).

FiledHolderPercentFiling
2025-09-17Morsevo Trade, Inc8%SCHEDULE 13D/A
2026-10-09Morsevo Trade, Inc6.7%SCHEDULE 13D/A
2026-10-19Morsevo Trade, Inc6.7%SCHEDULE 13D/A
DateRecordFigureOur pageSource
November 6, 2026Leadership change: Adriana Ebell departs, Chief Financial Officer, and 2 more—Leadership changesSource

Lunai Bioworks Inc.

At 5% or more2
Filings7
Latest filing2026-10-15

Lunai Bioworks Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-10. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Laksya Ventures Inc.9.6%22,163,978SCHEDULE 13G, 2025-09-262025-07-07
Hansen Hans Christian9.4%426,650SCHEDULE 13G, 2026-07-172026-05-22
William Anderson Wittekind4.5%226,665SCHEDULE 13D/A, 2026-10-152026-10-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Hansen Hans Christian0426,6500426,650SCHEDULE 13G, 2026-07-17
Hansen5751H ApS0426,6500426,650SCHEDULE 13G, 2026-07-17
Hansen5751V ApS0426,6500426,650SCHEDULE 13G, 2026-07-17
William Anderson Wittekind70,083156,58270,083156,582SCHEDULE 13D/A, 2026-10-15

The latest filing identifies Lunai Bioworks Inc. by CUSIP 29350E203 and gives its principal executive office as 2080 Century Park East, Suite 906, Los Angeles, CA 90067 (SCHEDULE 13D/A, 2026-10-15).

FiledHolderPercentFiling
2025-07-10William Anderson Wittekind8%SCHEDULE 13D/A
2025-09-26Laksya Ventures Inc.9.6%SCHEDULE 13G
2025-11-12William Anderson Wittekind7.8%SCHEDULE 13D/A
2025-11-28William Anderson Wittekind6.8%SCHEDULE 13D/A
2025-12-09William Anderson Wittekind6.8%SCHEDULE 13D/A
2026-07-17Hansen Hans Christian9.4%SCHEDULE 13G
2026-10-15William Anderson Wittekind4.5%SCHEDULE 13D/A
DateRecordFigureOur pageSource
October 23, 2026Leadership change: Nathen Fuentes departs, Chief Financial Officer, and 1 more—Leadership changesSource

Neurocrine Biosciences Inc

At 5% or more3
Filings6
Latest filing2026-10-30

Neurocrine Biosciences Inc has 6 Schedule 13D or 13G filings on record since 2026-01-21. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management5.23%5,257,941SCHEDULE 13G, 2026-04-302026-03-31
Jpmorgan Chase & Co.5.2%5,300,390SCHEDULE 13G/A, 2026-10-152026-09-30
Vanguard Portfolio Management5%5,083,540SCHEDULE 13G, 2026-10-302026-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management746,03705,257,9410SCHEDULE 13G, 2026-04-30
Jpmorgan Chase & Co.4,725,48522,4005,294,407665SCHEDULE 13G/A, 2026-10-15
Vanguard Portfolio Management23,50405,083,5400SCHEDULE 13G, 2026-10-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Neurocrine Biosciences Inc by CUSIP 64125C109 and gives its principal executive office as 12780 El Camino Real, San Diego, CA 92130 (SCHEDULE 13G, 2026-10-30).

FiledHolderPercentFiling
2026-01-21Jpmorgan Chase & Co.5.2%SCHEDULE 13G
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management5.23%SCHEDULE 13G
2026-07-27Jpmorgan Chase & Co.6.3%SCHEDULE 13G/A
2026-10-15Jpmorgan Chase & Co.5.2%SCHEDULE 13G/A
2026-10-30Vanguard Portfolio Management5%SCHEDULE 13G
DateRecordFigureOur pageSource
September 28, 2026Leadership change: Eiry W. Roberts appointed, Chief Medical Officer—Leadership changesSource
May 18, 2026Acquired Soleno Therapeutics, Inc.$2.90BAcquisitionSource

Novartis AG

At 5% or more2
Filings2
Latest filing2026-10-27

Novartis AG has 2 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.7.1%145,227,650SCHEDULE 13G/A, 2026-10-272026-09-30
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC6.4%139,602,467SCHEDULE 13G, 2025-07-172024-09-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.132,888,8460145,227,6500SCHEDULE 13G/A, 2026-10-27
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC126,084,21700139,602,467SCHEDULE 13G, 2025-07-17

The latest filing identifies Novartis AG by CUSIP H5820Q150 and gives its principal executive office as Lichtstrasse 35, Basel (SCHEDULE 13G/A, 2026-10-27).

FiledHolderPercentFiling
2025-07-17UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC6.4%SCHEDULE 13G
2026-10-27BlackRock, Inc.7.1%SCHEDULE 13G/A

Quantum Biopharma Ltd.

At 5% or more1
Filings8
Latest filing2026-10-05

Quantum Biopharma Ltd. has 8 Schedule 13D or 13G filings on record since 2025-07-10. 1 holder's latest filing reports 5% or more of class b subordinate voting shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Malone Wealth Ventures LLC9.8%375,752SCHEDULE 13G/A, 2026-02-032026-02-03
AdvisorShares Trust4.95%400,378SCHEDULE 13G/A, 2026-10-052026-09-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Malone Wealth Ventures LLC92,1800375,752—SCHEDULE 13G/A, 2026-02-03
AdvisorShares Trust400,3780400,3780SCHEDULE 13G/A, 2026-10-05

The latest filing identifies Quantum Biopharma Ltd. by CUSIP 74764Y205 and gives its principal executive office as 1 Adelaide Street East, Suite 801, Toronto (SCHEDULE 13G/A, 2026-10-05).

FiledHolderPercentFiling
2025-07-10Malone Wealth Ventures LLC19.9%SCHEDULE 13G/A
2025-07-10Malone Wealth Ventures LLC19.9%SCHEDULE 13G/A
2025-07-10Malone Wealth Ventures LLC19.4%SCHEDULE 13G/A
2025-07-18Malone Wealth Ventures LLC21.8%SCHEDULE 13G/A
2025-09-04Malone Wealth Ventures LLC27.4%SCHEDULE 13G/A
2026-02-03Malone Wealth Ventures LLC9.8%SCHEDULE 13G/A
2026-07-08AdvisorShares Trust5.33%SCHEDULE 13G
2026-10-05AdvisorShares Trust4.95%SCHEDULE 13G/A

REGENXBIO Inc.

At 5% or more3
Filings7
Latest filing2026-10-13

REGENXBIO Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-15. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Redmile Group, LLC9.9%5,062,477SCHEDULE 13G/A, 2025-08-142025-06-30
State Street Corporation5.3%2,731,553SCHEDULE 13G, 2026-05-122026-03-31
Jpmorgan Chase & Co.5.3%3,560,915SCHEDULE 13G, 2026-10-132026-09-30
BlackRock Portfolio Management LLC4.1%2,085,619SCHEDULE 13G/A, 2026-01-212025-12-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
State Street Corporation02,666,10502,731,553SCHEDULE 13G, 2026-05-12
Jpmorgan Chase & Co.3,324,34003,560,9150SCHEDULE 13G, 2026-10-13
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies REGENXBIO Inc. by CUSIP 75901B107 and gives its principal executive office as 9804 Medical Center Drive, Rockville, MD 20850 (SCHEDULE 13G, 2026-10-13).

FiledHolderPercentFiling
2025-07-15BlackRock Portfolio Management LLC6.2%SCHEDULE 13G
2025-08-14Redmile Group, LLC9.9%SCHEDULE 13G/A
2026-01-21BlackRock Portfolio Management LLC4.1%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-05-12State Street Corporation5.3%SCHEDULE 13G
2026-06-04Jpmorgan Chase & Co4.4%SCHEDULE 13G/A
2026-10-13Jpmorgan Chase & Co.5.3%SCHEDULE 13G
DateRecordFigureOur pageSource
October 16, 2026Leadership change: Kenneth T. Mills departs, Director—Leadership changesSource
August 25, 2026Leadership change: Gregory Ciongoli appointed, Director, and 1 more—Leadership changesSource

Repligen Corp

At 5% or more2
Filings8
Latest filing2026-10-07

Repligen Corp has 8 Schedule 13D or 13G filings on record since 2025-09-08. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Fmr LLC13%7,361,318SCHEDULE 13G/A, 2026-10-072026-09-30
Vanguard Capital Management5%2,825,579SCHEDULE 13G, 2026-07-312026-06-30
Roy T. Eddleman Living Trust4.81%2,705,689SCHEDULE 13G/A, 2026-02-132025-12-31
T. Rowe Price Associates, Inc.3.1%1,751,887SCHEDULE 13G/A, 2026-08-142026-06-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Fmr LLC7,345,27707,361,3180SCHEDULE 13G/A, 2026-10-07
Abigail P. Johnson007,361,3180SCHEDULE 13G/A, 2026-10-07
Vanguard Capital Management414,40802,825,5790SCHEDULE 13G, 2026-07-31
T. Rowe Price Associates, Inc.1,744,54901,751,8870SCHEDULE 13G/A, 2026-08-14
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Repligen Corp by CUSIP 759916109 and gives its principal executive office as 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA 02453 (SCHEDULE 13G/A, 2026-10-07).

FiledHolderPercentFiling
2025-09-08T. Rowe Price Associates, Inc.6.1%SCHEDULE 13G/A
2026-02-05Fmr LLC5.1%SCHEDULE 13G
2026-02-13Roy T. Eddleman Living Trust4.81%SCHEDULE 13G/A
2026-02-17T. Rowe Price Associates, Inc.8.2%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-07-31Vanguard Capital Management5%SCHEDULE 13G
2026-08-14T. Rowe Price Associates, Inc.3.1%SCHEDULE 13G/A
2026-10-07Fmr LLC13%SCHEDULE 13G/A
DateRecordFigureOur pageSource
September 15, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

REX AMERICAN RESOURCES Corp

At 5% or more3
Filings6
Latest filing2026-10-19

REX AMERICAN RESOURCES Corp has 6 Schedule 13D or 13G filings on record since 2025-08-11. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.14.3%4,732,063SCHEDULE 13G/A, 2025-10-172025-09-30
Dimensional Fund Advisors LP13%2,152,938SCHEDULE 13G/A, 2025-10-092025-09-30
Rose Stuart A8.6%2,851,418SCHEDULE 13G/A, 2026-10-192026-09-30
Renaissance Technologies LLC4.84%1,595,630SCHEDULE 13G/A, 2026-02-122025-12-31
State Street Corporation4.8%784,248SCHEDULE 13G, 2025-08-112025-06-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.4,660,64004,732,0630SCHEDULE 13G/A, 2025-10-17
Rose Stuart A2,851,418—2,851,418—SCHEDULE 13G/A, 2026-10-19
Renaissance Technologies LLC1,595,63001,595,6300SCHEDULE 13G/A, 2026-02-12
Renaissance Technologies Holdings Corporation1,595,63001,595,6300SCHEDULE 13G/A, 2026-02-12
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies REX AMERICAN RESOURCES Corp by CUSIP 761624105 and gives its principal executive office as 7720 PARAGON ROAD, DAYTON, OH 45459 (SCHEDULE 13G/A, 2026-10-19).

FiledHolderPercentFiling
2025-08-11State Street Corporation4.8%SCHEDULE 13G
2025-10-09Dimensional Fund Advisors LP13%SCHEDULE 13G/A
2025-10-17BlackRock, Inc.14.3%SCHEDULE 13G/A
2026-02-12Renaissance Technologies LLC4.84%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-10-19Rose Stuart A8.6%SCHEDULE 13G/A
DateRecordFigureOur pageSource
July 1, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

Rhythm Pharmaceuticals, Inc.

At 5% or more5
Filings11
Latest filing2026-10-13

Rhythm Pharmaceuticals, Inc. has 11 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
RA Capital Management, L.P.9.9%6,666,837SCHEDULE 13G/A, 2026-02-172025-12-31
Primecap Management Co5.21%3,478,669SCHEDULE 13G/A, 2026-02-122025-12-31
Perceptive Advisors LLC5.1%3,519,626SCHEDULE 13G/A, 2026-05-152026-03-31
Jpmorgan Chase & Co.5.1%3,563,667SCHEDULE 13G, 2026-10-132026-09-30
Vanguard Capital Management5.02%3,432,949SCHEDULE 13G, 2026-04-302026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Perceptive Advisors LLC03,519,62603,519,626SCHEDULE 13G/A, 2026-05-15
Joseph Edelman03,519,62603,519,626SCHEDULE 13G/A, 2026-05-15
Perceptive Life Sciences Master Fund, Ltd.02,790,46102,790,461SCHEDULE 13G/A, 2026-05-15
Perceptive Capital Solutions Holdings LP0729,1650729,165SCHEDULE 13G/A, 2026-05-15
Jpmorgan Chase & Co.3,358,21613,560,98372SCHEDULE 13G, 2026-10-13
Vanguard Capital Management465,12403,432,9490SCHEDULE 13G, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Rhythm Pharmaceuticals, Inc. by CUSIP 76243J105 and gives its principal executive office as 222 Berkeley Street, 12th Floor, Boston, MA 02116 (SCHEDULE 13G, 2026-10-13).

FiledHolderPercentFiling
2025-08-14Primecap Management Co7.67%SCHEDULE 13G/A
2025-08-14RA Capital Management, L.P.8.7%SCHEDULE 13G/A
2025-10-30The Vanguard Group7.52%SCHEDULE 13G/A
2025-11-14Primecap Management Co6.42%SCHEDULE 13G/A
2026-01-30The Vanguard Group9.3%SCHEDULE 13G/A
2026-02-12Primecap Management Co5.21%SCHEDULE 13G/A
2026-02-17RA Capital Management, L.P.9.9%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management5.02%SCHEDULE 13G
2026-05-15Perceptive Advisors LLC5.1%SCHEDULE 13G/A
2026-10-13Jpmorgan Chase & Co.5.1%SCHEDULE 13G

Rpm International Inc

At 5% or more5
Filings6
Latest filing2026-10-27

Rpm International Inc has 6 Schedule 13D or 13G filings on record since 2025-08-11. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.9.2%11,699,623SCHEDULE 13G/A, 2026-10-272026-09-30
Aristotle Capital Management, LLC6.32%8,104,789SCHEDULE 13G/A, 2025-11-142025-09-30
Vanguard Portfolio Management5.6%7,177,004SCHEDULE 13G, 2026-04-292026-03-31
Vanguard Capital Management5.23%6,709,171SCHEDULE 13G, 2026-04-302026-03-31
State Street Corporation5.1%6,539,364SCHEDULE 13G, 2025-08-112025-06-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.11,236,656011,699,6230SCHEDULE 13G/A, 2026-10-27
Vanguard Portfolio Management15,38707,177,0040SCHEDULE 13G, 2026-04-29
Vanguard Capital Management955,45506,709,1710SCHEDULE 13G, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Rpm International Inc by CUSIP 749685103 and gives its principal executive office as 2628 PEARL RD PO BOX 777, MEDINA, OH 44258 (SCHEDULE 13G/A, 2026-10-27).

FiledHolderPercentFiling
2025-08-11State Street Corporation5.1%SCHEDULE 13G
2025-11-14Aristotle Capital Management, LLC6.32%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Portfolio Management5.6%SCHEDULE 13G
2026-04-30Vanguard Capital Management5.23%SCHEDULE 13G
2026-10-27BlackRock, Inc.9.2%SCHEDULE 13G/A
DateRecordFigureOur pageSource
November 6, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource
July 22, 2026Leadership change: David C. Dennsteadt appointed, Chief Operating Officer—Leadership changesSource
June 2, 2026Leadership change: Timothy R. Kinser departs, Vice President—Leadership changesSource
April 23, 2026Leadership change: Thomas C. Gentile appointed, and 1 more—Leadership changesSource

Sanofi

At 5% or more1
Filings6
Latest filing2026-10-26

Sanofi has 6 Schedule 13D or 13G filings on record since 2025-08-13. 1 holder's latest filing reports 5% or more of common stock/american depositary receipts/convertible bonds. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Amundi5.7%68,832,052SCHEDULE 13G/A, 2026-10-262026-09-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Amundi034,587,207034,244,845SCHEDULE 13G/A, 2026-10-26
Amundi Asset Management034,587,207034,244,845SCHEDULE 13G/A, 2026-10-26

The latest filing identifies Sanofi by CUSIP 80105N105 and gives its principal executive office as 46 avenue de la Grande Armee, Paris (SCHEDULE 13G/A, 2026-10-26).

FiledHolderPercentFiling
2025-08-13Amundi5.03%SCHEDULE 13G/A
2025-11-14Amundi5.21%SCHEDULE 13G/A
2026-02-17Amundi5.11%SCHEDULE 13G/A
2026-04-10Amundi5.04%SCHEDULE 13G/A
2026-07-22Amundi5.65%SCHEDULE 13G/A
2026-10-26Amundi5.7%SCHEDULE 13G/A

Sellas Life Sciences Group Inc

At 5% or more3
Filings11
Latest filing2026-10-27

Sellas Life Sciences Group Inc has 11 Schedule 13D or 13G filings on record since 2025-07-29. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.7.9%15,872,685SCHEDULE 13G/A, 2026-10-272026-09-30
State Street Corporation7%12,996,558SCHEDULE 13G, 2026-08-072026-06-30
Vanguard Capital Management5.19%9,666,278SCHEDULE 13G, 2026-07-312026-06-30
Anson Funds Management LP4.9%7,481,178SCHEDULE 13G/A, 2026-02-172025-12-31
Highbridge Capital Management, LLC3.7%6,514,658SCHEDULE 13G/A, 2026-01-302025-12-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.15,499,019015,872,6850SCHEDULE 13G/A, 2026-10-27
State Street Corporation012,677,559012,996,558SCHEDULE 13G, 2026-08-07
Vanguard Capital Management1,400,17309,666,2780SCHEDULE 13G, 2026-07-31

The latest filing identifies Sellas Life Sciences Group Inc by CUSIP 81642T209 and gives its principal executive office as 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY 10036 (SCHEDULE 13G/A, 2026-10-27).

FiledHolderPercentFiling
2025-07-29The Vanguard Group6.7%SCHEDULE 13G
2025-08-14Anson Funds Management LP4.9%SCHEDULE 13G/A
2025-10-17BlackRock, Inc.5.4%SCHEDULE 13G
2025-11-14Anson Funds Management LP5.7%SCHEDULE 13G
2026-01-30Highbridge Capital Management, LLC3.7%SCHEDULE 13G/A
2026-02-17Anson Funds Management LP4.9%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-24BlackRock, Inc.6.8%SCHEDULE 13G/A
2026-07-31Vanguard Capital Management5.19%SCHEDULE 13G
2026-08-07State Street Corporation7%SCHEDULE 13G
2026-10-27BlackRock, Inc.7.9%SCHEDULE 13G/A

Stepan Co

At 5% or more2
Filings4
Latest filing2026-10-08

Stepan Co has 4 Schedule 13D or 13G filings on record since 2026-01-21. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: about 100 jobs, latest 2026-07-29 (layoff filings and notices).

HolderPercentSharesLatestEvent date
Vanguard Portfolio Management6.04%1,372,514SCHEDULE 13G, 2026-04-292026-03-31
Dimensional Fund Advisors LP5.2%1,192,015SCHEDULE 13G, 2026-10-082026-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Portfolio Management13,66101,372,5140SCHEDULE 13G, 2026-04-29
Dimensional Fund Advisors LP1,165,50301,192,0150SCHEDULE 13G, 2026-10-08
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Stepan Co by CUSIP 858586100 and gives its principal executive office as 1101 Skokie Blvd, Suite 500, Northbrook (SCHEDULE 13G, 2026-10-08).

FiledHolderPercentFiling
2026-01-21Dimensional Fund Advisors LP5%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Portfolio Management6.04%SCHEDULE 13G
2026-10-08Dimensional Fund Advisors LP5.2%SCHEDULE 13G
DateRecordFigureOur pageSource
July 29, 2026Leadership change: Jan Stern Reed departs, and 1 more—Leadership changesSource

Tg Therapeutics, Inc.

At 5% or more3
Filings4
Latest filing2026-10-27

Tg Therapeutics, Inc. has 4 Schedule 13D or 13G filings on record since 2025-11-10. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.13.8%21,190,534SCHEDULE 13G/A, 2026-10-272026-09-30
Vanguard Portfolio Management5.26%8,400,210SCHEDULE 13G, 2026-04-292026-03-31
State Street Corporation5.1%8,100,619SCHEDULE 13G, 2025-11-102025-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.20,848,777021,190,5340SCHEDULE 13G/A, 2026-10-27
Vanguard Portfolio Management126,23108,400,2100SCHEDULE 13G, 2026-04-29
State Street Corporation07,634,70008,100,619SCHEDULE 13G, 2025-11-10
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Tg Therapeutics, Inc. by CUSIP 88322Q108 and gives its principal executive office as 3020 Carrington Mill Blvd, Suite 475, Morrisville, NC 27560 (SCHEDULE 13G/A, 2026-10-27).

FiledHolderPercentFiling
2025-11-10State Street Corporation5.1%SCHEDULE 13G
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Portfolio Management5.26%SCHEDULE 13G
2026-10-27BlackRock, Inc.13.8%SCHEDULE 13G/A

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All 5%+ stakes

RSS